SCHEMBL4189384

SCHEMBL4189384

COc1cc(OC)c(/C=C(\C#N)S(=O)(=O)Cc2ccc(F)cc2)c(OC)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
CYP1A2 P05177 2/20 0.43
CYP3A4 P08684 2/20 0.43
ALDH1A1 P00352 2/20 0.43
CYP2C19 P33261 1/20 0.43
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA9 Q16790 1/20 0.43
PTPN7 P35236 1/20 0.40
PTPN12 Q05209 1/20 0.40
PTPN22 Q9Y2R2 1/20 0.40
EGFR P00533 2/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
ERBB2 P04626 1/20 0.39
NQO2 P16083 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4189392 1.00 MAOA (0.46) MAOASMN1; SMN2NPC1RAB9ACYP1A2
SCHEMBL4189389 1.00 MAOA (0.46) MAOASMN1; SMN2NPC1RAB9ACYP1A2
SCHEMBL4175736 0.91 CYP1A2 (0.45) SMN1; SMN2CYP1A2CYP3A4ALDH1A1CYP2C19
SCHEMBL4175730 0.91 CYP1A2 (0.45) SMN1; SMN2CYP1A2CYP3A4ALDH1A1CYP2C19
SCHEMBL4175733 0.91 CYP1A2 (0.45) SMN1; SMN2CYP1A2CYP3A4ALDH1A1CYP2C19
SCHEMBL4179035 0.88 CA12 (0.41) CYP1A2CYP3A4ALDH1A1CYP2C19CA12
SCHEMBL4179043 0.88 CA12 (0.41) CYP1A2CYP3A4ALDH1A1CYP2C19CA12
SCHEMBL4179031 0.88 CA12 (0.41) CYP1A2CYP3A4ALDH1A1CYP2C19CA12
SCHEMBL4191769 0.88 ALDH1A1 (0.46) CYP1A2CYP3A4ALDH1A1CYP2C19CA12
SCHEMBL4189374 0.88 NQO2 (0.47) PTPN7PTPN12PTPN22EGFRMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090191193-A1 Aryl Vinyl Sulfides, Sulfones, Sulfoxides and Sulfonamides, Derivatives Thereof and Therapeutic Uses Thereof TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2009-07-30 US claimed
EP-2046322-A2 ARYL VINYL SULFIDES, SULFONES, SULFOXIDES AND SULFONAMIDES, DERIVATIVES THEREOF AND THERAPEUTIC USES THEREOF Temple University of the Commonwealth System of Higher Education (US) 2009-04-15 EP claimed
WO-2008016682-A2 ARYL VINYL SULFIDES, SULFONES, SULFOXIDES AND SULFONAMIDES, DERIVATIVES THEREOF AND THERAPEUTIC USES THEREOF TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2008-02-07 WO claimed
US-20090191193-A1 Aryl Vinyl Sulfides, Sulfones, Sulfoxides and Sulfonamides, Derivatives Thereof and Therapeutic Uses Thereof TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2009-07-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090191193-A1 Aryl Vinyl Sulfides, Sulfones, Sulfoxides and Sulfonamides, Derivatives Thereof and Therapeutic Uses Thereof ARSA, STS, SULT2A1 MAOA 4530/4885SMN1; SMN2 448/4885NPC1 4546/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.